LP067

LP067 is an investigational oral formulation of doxepin being developed by LIPIN Pharmaceutical (Xiamen) for the treatment of insomnia disorder. It is currently in Phase 1 clinical development, where it is being evaluated for relative bioavailability and pharmacokinetics in comparison to the reference drug Silenor (low-dose doxepin hydrochloride). Doxepin, when administered at low doses, acts as a potent and selective antagonist of the histamine H1 receptor, which is involved in the regulation of the sleep-wake cycle. By blocking H1 receptors, the drug helps patients with sleep maintenance insomnia. LIPIN Pharmaceutical specializes in advanced drug delivery technologies, suggesting LP067 may utilize a proprietary formulation to optimize the delivery of doxepin.